Wedbush Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Posted by Brenda Bartman on Jun 30th, 2026

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) had its price objective lifted by Wedbush from $32.00 to $43.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price target suggests a potential upside of 128.85% from the stock’s current price.

A number of other research firms have also weighed in on VRDN. Evercore set a $26.00 target price on shares of Viridian Therapeutics in a report on Friday, May 15th. Royal Bank Of Canada raised their price target on shares of Viridian Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Stifel Nicolaus set a $39.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, May 13th. HC Wainwright decreased their price target on shares of Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Finally, Wall Street Zen upgraded Viridian Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, June 14th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.79.

Get Our Latest Stock Report on VRDN

Viridian Therapeutics Stock Up 5.0%

VRDN stock opened at $18.79 on Tuesday. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $1.94 billion, a PE ratio of -5.66 and a beta of 0.90. Viridian Therapeutics has a twelve month low of $13.18 and a twelve month high of $34.29. The stock has a 50-day simple moving average of $16.34 and a two-hundred day simple moving average of $24.12.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. The firm had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.04 million. During the same period in the prior year, the firm posted ($0.87) earnings per share. The company’s revenue for the quarter was up 95.8% on a year-over-year basis. On average, equities analysts predict that Viridian Therapeutics will post -3.87 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the company’s stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $19,999,990.00. Following the completion of the transaction, the director directly owned 5,090,928 shares in the company, valued at $86,545,776. This trade represents a 30.05% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Viridian Therapeutics

A number of institutional investors have recently made changes to their positions in VRDN. KBC Group NV purchased a new stake in shares of Viridian Therapeutics during the 1st quarter valued at $34,000. Aster Capital Management DIFC Ltd purchased a new position in Viridian Therapeutics in the third quarter worth $35,000. ANTIPODES PARTNERS Ltd purchased a new position in Viridian Therapeutics in the fourth quarter worth $36,000. Larson Financial Group LLC bought a new position in Viridian Therapeutics in the third quarter valued at $52,000. Finally, US Bancorp DE increased its stake in Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after acquiring an additional 463 shares during the last quarter.

Viridian Therapeutics Company Profile

(Get Free Report)

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.